Aurinia Pharmaceuticals Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Aurinia Pharmaceuticals Inc. (AUPH) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Amount of $1.97 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationOtherAdjustments · last filed 2026-02-26
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2025 was $1.97M, a 809.22% increase from fiscal 2024.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2024 was $217.00K, a 334.00% increase from fiscal 2023.
- Aurinia Pharmaceuticals Inc. effective income tax rate reconciliation, other adjustments, amount for fiscal 2023 was $50.00K.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount 12 month |
|---|---|
| 2025-12-31 | $1.97M 10-K · filed 2026-02-26 |
| 2024-12-31 | $217.00K 10-K · filed 2026-02-26 |
| 2023-12-31 | $50.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |